
Terremoto Biosciences Receives FDA Fast Track for TER-2013 AKT1-Selective Inhibitor in Breast Cancer
Terremoto Biosciences Receives FDA Fast Track Designation for TER-2013 in Advanced HR+/HER2- Breast Cancer Terremoto Biosciences, a biotechnology company focused on developing highly targeted small-molecule therapies for cancer, has announced…












